Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences industry. Eli Lilly has reported positive topline results from the Triumph-2 and Triumph-3 Phase III trials of Retatrutide, an investigational once-weekly triple hormone receptor agonist targeting GIP, GLP-1, and glucagon receptors. With five positive Phase III trials now complete, Lilly plans to submit a biologics license application to FDA in the first quarter of 2027. She says that shorter-term thinking has turned GLP-1 coverage into a budget line item rather than a long-term population health strategy. Thanks for listening to Pharmaceutical Executive Daily.